Figure 2
The differences of morphology, MMP9 and PCNA expression of TA2 breast cancer between the control and treatment groups. A. The morphologic characteristics of TA2 breast cancer in the control and treatment groups (HE staining, ×200). a. DMSO group. b. CoCl2 group. c. Glibenclamide group. d. CoCl2 + glibenclamide group. e. Paclitaxel group. B. Immunohistochemical staining for MMP9 and PCNA in the control and treatment groups (immunohistochemical staining, ×200). a. MMP9 staining of DMSO group. b. MMP9 staining of CoCl2 group. c. MMP9 staining of Glibenclamide group. d. MMP9 staining of CoCl2 + glibenclamide group. e. MMP9 staining of paclitaxel group. f. PCNA staining of DMSO group. g. PCNA staining of CoCl2 group. h. PCNA staining of Glibenclamide group. i. PCNA staining of CoCl2 + glibenclamide group. j. PCNA staining of paclitaxel group.